{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T16:03:11Z","timestamp":1789833791484,"version":"4.0.1"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2026,11,1]],"date-time":"2026-11-01T00:00:00Z","timestamp":1793491200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["31070820"],"award-info":[{"award-number":["31070820"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007540","name":"Jiangsu Provincial Agricultural Science and Technology Innovation Fund","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007540","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012659","name":"Foundation for Innovative Research Groups of the National Natural Science Foundation of China","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100012659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100012154","name":"Graduate Research and Innovation Projects of Jiangsu Province","doi-asserted-by":"publisher","award":["KYCX24-4149"],"award-info":[{"award-number":["KYCX24-4149"]}],"id":[{"id":"10.13039\/501100012154","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Microbial Pathogenesis"],"published-print":{"date-parts":[[2026,11]]},"DOI":"10.1016\/j.micpath.2026.108798","type":"journal-article","created":{"date-parts":[[2026,8,28]],"date-time":"2026-08-28T15:30:54Z","timestamp":1787931054000},"page":"108798","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"special_numbering":"C","title":["A novel Fc-optimized anti-Ebola neutralizing antibody with extended in vivo half-life"],"prefix":"10.1016","volume":"220","author":[{"given":"Shangde","family":"Peng","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihan","family":"Yi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wen","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fenghao","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyi","family":"Zhou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiannan","family":"Feng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yan","family":"Wen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guojiang","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3789-8806","authenticated-orcid":false,"given":"Chunxia","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"12","key":"10.1016\/j.micpath.2026.108798_bib1","doi-asserted-by":"crossref","first-page":"2083","DOI":"10.1007\/s00705-010-0814-x","article-title":"Proposal for a revised taxonomy of the family filoviridae: classification, names of taxa and viruses, and virus abbreviations","volume":"155","author":"Kuhn","year":"2010","journal-title":"Arch. Virol."},{"key":"10.1016\/j.micpath.2026.108798_bib2","article-title":"Ebola virus disease","year":"2014","journal-title":"Arch. Orig."},{"issue":"3","key":"10.1016\/j.micpath.2026.108798_bib3","doi-asserted-by":"crossref","first-page":"285","DOI":"10.1016\/j.jiph.2022.01.005","article-title":"A systematic review of ebola virus disease outbreaks and an analysis of the efficacy and safety of newer drugs approved for the treatment of ebola virus disease by the us food and drug administration from 2016 to 2020","volume":"15","author":"Sivanandy","year":"2022","journal-title":"J. Infect. Public Health"},{"issue":"329","key":"10.1016\/j.micpath.2026.108798_bib4","doi-asserted-by":"crossref","first-page":"329ra33","DOI":"10.1126\/scitranslmed.aad9875","article-title":"Two-mab cocktail protects macaques against the makona variant of ebola virus","volume":"8","author":"Qiu","year":"2016","journal-title":"Sci. Transl. Med."},{"issue":"Suppl 1","key":"10.1016\/j.micpath.2026.108798_bib5","doi-asserted-by":"crossref","first-page":"42","DOI":"10.1186\/s12864-017-4328-8","article-title":"Mapping HLA-A2, -A3 and -B7 supertype-restricted T-cell epitopes in the ebolavirus proteome","volume":"19","author":"Lim","year":"2018","journal-title":"BMC Genom."},{"issue":"3","key":"10.1016\/j.micpath.2026.108798_bib6","first-page":"57","article-title":"General introduction into the Ebola virus biology and disease","volume":"54","author":"Zawili\u0144ska","year":"2014","journal-title":"Folia Med. Crac."},{"issue":"5","key":"10.1016\/j.micpath.2026.108798_bib7","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003258","article-title":"The secret life of viral entry glycoproteins: moonlighting in immune evasion","volume":"9","author":"Cook","year":"2013","journal-title":"PLoS Pathog."},{"issue":"1","key":"10.1016\/j.micpath.2026.108798_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/s13337-015-0293-5","article-title":"Viral glycoproteins: biological role and application in diagnosis","volume":"27","author":"Banerjee","year":"2016","journal-title":"Virusdisease"},{"issue":"6","key":"10.1016\/j.micpath.2026.108798_bib9","doi-asserted-by":"crossref","first-page":"1180","DOI":"10.3201\/eid2806.212223","article-title":"Effect of recombinant vesicular stomatitis virus-zaire ebola virus vaccination on ebola virus disease illness and death, democratic Republic of the Congo","volume":"28","author":"Rupani","year":"2022","journal-title":"Emerg. Infect. Dis."},{"issue":"3","key":"10.1016\/j.micpath.2026.108798_bib10","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003232","article-title":"TIM-family proteins promote infection of multiple enveloped viruses through virion-associated phosphatidylserine","volume":"9","author":"Jemielity","year":"2013","journal-title":"PLoS Pathog."},{"issue":"12","key":"10.1016\/j.micpath.2026.108798_bib11","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1003065","article-title":"Antigenic subversion: a novel mechanism of host immune evasion by ebola virus","volume":"8","author":"Mohan","year":"2012","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.micpath.2026.108798_bib12","unstructured":"Evidence to Recommendations for rVSV\u0394G-ZEBOV-GP Ebola Vaccine for Persons in the U.S. Population who are at Potential Occupational Risk of Exposure to Ebola Virus (Species Zaire ebolavirus)."},{"key":"10.1016\/j.micpath.2026.108798_bib13","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.721328","article-title":"Review: insights on current FDA-approved monoclonal antibodies against ebola virus infection","volume":"12","author":"Tshiani Mbaya","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.micpath.2026.108798_bib14","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1016\/j.coph.2021.07.020","article-title":"Therapeutics development for ebola virus disease: a recent scenario","volume":"60","author":"Chakraborty","year":"2021","journal-title":"Curr. Opin. Pharmacol."},{"issue":"24","key":"10.1016\/j.micpath.2026.108798_bib15","doi-asserted-by":"crossref","first-page":"2293","DOI":"10.1056\/NEJMoa1910993","article-title":"A randomized, controlled trial of ebola virus disease therapeutics","volume":"381","author":"Mulangu","year":"2019","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.micpath.2026.108798_bib16","doi-asserted-by":"crossref","first-page":"2365","DOI":"10.1056\/NEJMe1915350","article-title":"Monoclonal antibody therapy for ebola virus disease","volume":"381","author":"Levine","year":"2019","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.micpath.2026.108798_bib17","unstructured":"Antibody Manufactured at Frederick National Laboratory Receives FDA Approval to Treat Ebola Virus Disease."},{"issue":"50","key":"10.1016\/j.micpath.2026.108798_bib18","doi-asserted-by":"crossref","first-page":"1162","DOI":"10.15585\/mmwr.mm6850a3","article-title":"Ebola virus disease outbreak - democratic Republic of the Congo, August 2018-November 2019","volume":"68","author":"Aruna","year":"2019","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"issue":"8","key":"10.1016\/j.micpath.2026.108798_bib19","first-page":"20","article-title":"Standardized economic cost modeling for next-generation MAb production","volume":"14","author":"Pollard","year":"2016","journal-title":"Bioprocess Int."},{"issue":"5","key":"10.1016\/j.micpath.2026.108798_bib20","doi-asserted-by":"crossref","first-page":"691","DOI":"10.1177\/31.5.6341459","article-title":"Monoclonal antibody storage conditions, and concentration effects on immunohistochemical specificity","volume":"31","author":"Ciocca","year":"1983","journal-title":"Histochem. Cytochem."},{"issue":"4","key":"10.1016\/j.micpath.2026.108798_bib21","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0036192","article-title":"Protective efficacy of neutralizing monoclonal antibodies in a nonhuman primate model of ebola hemorrhagic fever","volume":"7","author":"Marzi","year":"2012","journal-title":"PLoS One"},{"issue":"1","key":"10.1016\/j.micpath.2026.108798_bib22","doi-asserted-by":"crossref","DOI":"10.1128\/jvi.01400-24","article-title":"Structural basis of different neutralization capabilities of monoclonal antibodies against H7N9 virus","volume":"99","author":"Zhao","year":"2025","journal-title":"J. Virol."},{"issue":"10","key":"10.1016\/j.micpath.2026.108798_bib23","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.18520\/cs\/v114\/i10\/2194-2195","article-title":"Annual review of biomedical engineering","volume":"114","author":"Agarwal","year":"2017","journal-title":"Curr. Sci."},{"issue":"10","key":"10.1016\/j.micpath.2026.108798_bib24","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics15102402","article-title":"Fc-Engineered therapeutic antibodies: recent advances and future directions","volume":"15","author":"Abdeldaim","year":"2023","journal-title":"Pharmaceutics"},{"issue":"9","key":"10.1016\/j.micpath.2026.108798_bib25","doi-asserted-by":"crossref","first-page":"5171","DOI":"10.4049\/jimmunol.169.9.5171","article-title":"Increasing the affinity of a human IgG1 for the neonatal Fc receptor: biological consequences","volume":"169","author":"Dall'Acqua","year":"2002","journal-title":"J. Immunol."},{"issue":"33","key":"10.1016\/j.micpath.2026.108798_bib26","doi-asserted-by":"crossref","first-page":"23514","DOI":"10.1074\/jbc.M604292200","article-title":"Properties of human IgG1s engineered for enhanced binding to the neonatal Fc receptor (FcRn)","volume":"281","author":"Dall'Acqua","year":"2006","journal-title":"J. Biol. Chem."},{"issue":"12","key":"10.1016\/j.micpath.2026.108798_bib27","doi-asserted-by":"crossref","first-page":"6147","DOI":"10.1128\/AAC.01285-13","article-title":"A novel investigational Fc-modified humanized monoclonal antibody, motavizumab-YTE, has an extended half-life in healthy adults","volume":"57","author":"Robbie","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"issue":"6","key":"10.1016\/j.micpath.2026.108798_bib28","doi-asserted-by":"crossref","first-page":"530","DOI":"10.1182\/blood-2018-09-876136","article-title":"Ravulizumab (ALXN1210) vs eculizumab in adult patients with PNH naive to complement inhibitors: the 301 study","volume":"133","author":"Lee","year":"2019","journal-title":"Blood"},{"issue":"11","key":"10.1016\/j.micpath.2026.108798_bib29","doi-asserted-by":"crossref","first-page":"1850","DOI":"10.1038\/s12276-022-00870-5","article-title":"An Fc variant with two mutations confers prolonged serum half-life and enhanced effector functions on IgG antibodies","volume":"54","author":"Ko","year":"2022","journal-title":"Exp. Mol. Med."},{"key":"10.1016\/j.micpath.2026.108798_bib30","series-title":"Bethesda (MD): National Institute of Diabetes and Digestive and Kidney Diseases","year":"2012"},{"issue":"4","key":"10.1016\/j.micpath.2026.108798_bib31","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s40263-023-00995-9","article-title":"Satralizumab: a review in neuromyelitis optica spectrum disorder","volume":"37","author":"Fung","year":"2023","journal-title":"CNS Drugs"},{"key":"10.1016\/j.micpath.2026.108798_bib32","series-title":"Discovery and Characterization of a Novel High-Affinity Anti-TL1A Monoclonal Antibody with Extended Half-Life for the Treatment of Inflammatory Bowel Disease[J]","author":"Ernst","year":"2024"},{"key":"10.1016\/j.micpath.2026.108798_bib33","article-title":"A high-potency extended half-life Anti-TL1A antibody, to be developed for patients with","year":"2024","journal-title":"Inflam. Bowel Dis."},{"key":"10.1016\/j.micpath.2026.108798_bib34","series-title":"Xencor Enters Global Collaboration and License Agreement with Janssen to Advance Plamotamab and Xmab CD28 Bispecific Antibody Combinations for the Treatment of Patients with B-Cell Malignancies[Eb]","year":"2021"},{"key":"10.1016\/j.micpath.2026.108798_bib35","series-title":"Xencor Doses First Subject in Phase 1\/2 Study of XmAb\u00ae942 in Development for Patients with Inflammatory Bowel Disease[Eb]","year":"2024"},{"issue":"8","key":"10.1016\/j.micpath.2026.108798_bib36","doi-asserted-by":"crossref","first-page":"376","DOI":"10.3390\/toxins17080376","article-title":"A novel Anti-BoNT\/A neutralizing antibody possessed overlapped epitope with SV2 and had prolonged half-life in vivo","volume":"17","author":"Peng","year":"2025","journal-title":"Toxins"},{"key":"10.1016\/j.micpath.2026.108798_bib37","doi-asserted-by":"crossref","DOI":"10.1016\/j.pep.2022.106071","article-title":"Expression, purification and characterization of SARS-CoV-2 spike RBD in ExpiCHO cells","volume":"194","author":"De March","year":"2022","journal-title":"Protein Expr. Purif."},{"issue":"1","key":"10.1016\/j.micpath.2026.108798_bib38","doi-asserted-by":"crossref","first-page":"680","DOI":"10.1080\/22221751.2020.1743767","article-title":"Establishment and validation of a pseudovirus neutralization assay for SARS-CoV-2","volume":"9","author":"Nie","year":"2020","journal-title":"Emerg. Microb. Infect."},{"issue":"9","key":"10.1016\/j.micpath.2026.108798_bib39","doi-asserted-by":"crossref","first-page":"2563","DOI":"10.1084\/jem.20170161","article-title":"Marburg virus survivor immune responses are Th1 skewed with limited neutralizing antibody responses","volume":"214","author":"Stonier","year":"2017","journal-title":"J. Exp. Med."}],"container-title":["Microbial Pathogenesis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401026005243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0882401026005243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,19]],"date-time":"2026-09-19T15:20:59Z","timestamp":1789831259000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0882401026005243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,11]]},"references-count":39,"alternative-id":["S0882401026005243"],"URL":"https:\/\/doi.org\/10.1016\/j.micpath.2026.108798","relation":{},"ISSN":["0882-4010"],"issn-type":[{"value":"0882-4010","type":"print"}],"subject":[],"published":{"date-parts":[[2026,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A novel Fc-optimized anti-Ebola neutralizing antibody with extended in vivo half-life","name":"articletitle","label":"Article Title"},{"value":"Microbial Pathogenesis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.micpath.2026.108798","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 Elsevier Ltd. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"108798"}}